Skip to main content

Crohn's Disease News

Related terms: Crohns

Monthly News Roundup - March 2025

FDA Approves Tremfya for Adults Patients with Active Crohn’s Disease In March, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of Tremfya (guselkumab) for the t...

FDA Approves Tremfya for Active Crohn Disease in Adults

MONDAY, March 24, 2025 – The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth...

Chronic Conditions and Their Age of Onset Predict Health Trajectory in IBD

MONDAY, March 24, 2025 – Among people with inflammatory bowel disease (IBD), conditions developed at or before age 60 years and their age of onset are important for predicting premature death,...

FDA Approves Tremfya (guselkumab) for Adult Patients with Moderately to Severely Active Crohn’s Disease

HORSHAM, Pa. (March 20, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab), the first and only IL-23 inhibitor o...

IBD Activity May Increase Risk for Clostridioides Difficile Infection

WEDNESDAY, March 5, 2025 – For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis, corticosteroid usage,...

Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease

WEDNESDAY, Feb 5, 2025 – Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a study published in the March issue of...

Metrics From Wearable Devices Can Predict IBD Flares

FRIDAY, Jan. 24, 2025 – Physiological metrics from wearable devices can help identify inflammatory bowel disease (IBD) flares, according to a study published online Jan. 16 in Gastroenterology....

FDA Approves Omvoh for Moderately to Severely Active Crohn Disease

THURSDAY, Jan. 16, 2025 – The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, according to a press...

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment...

Early Anti-TNFα Therapy Cuts Perianal Fistula Complications in Pediatric Crohn Disease

FRIDAY, Jan. 3, 2025 – For pediatric patients with Crohn disease, early anti-tumor necrosis factor-alpha (anti-TNFα) therapy is beneficial in preventing the development of perianal fistula ...

Intestinal Ultrasound Feasible for Detecting Pediatric Inflammatory Bowel Disease

FRIDAY, Jan. 3, 2025 – Intestinal ultrasound (IU) can be considered a screening tool for pediatric inflammatory bowel disease (IBD), according to a study published online Dec. 24 in the Journal of ...

Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease

FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. A new study published recently in the journal Gut shows c...

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...

Inflammatory Bowel Disease on the Rise Globally in the Elderly

WEDNESDAY, Dec. 4, 2024 -- Inflammatory bowel disease (IBD) in older adults has become a global public health burden, according to a study published in the Jan. 31, 2025, issue of Autoimmunity R...

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Crohn's Disease - Maintenance, Crohn's Disease - Acute, Inflammatory Bowel Disease

Related drug support groups

Humira, Stelara, Entyvio, Remicade, Skyrizi, cholestyramine, adalimumab, budesonide, ustekinumab, Cimzia